SML0040
洛美曲索水合物
≥95% (HPLC), powder, GARFTase inhibitor
别名:
LY 264618水合物, N-[4-[2-[(6R)-2-氨基-3,4,5,6,7,8-四氢-4-氧吡啶并[2,3-d]嘧啶-6-基]乙基]苯甲酰基]-L-谷氨酸水合物
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C21H25N5O6 · xH2O
化学文摘社编号:
分子量:
443.45 (anhydrous basis)
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
产品名称
洛美曲索水合物, ≥95% (HPLC)
SMILES string
O.NC1=NC(=O)C2=C(NC[C@H](CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C2)N1
InChI
1S/C21H25N5O6.H2O/c22-21-25-17-14(19(30)26-21)9-12(10-23-17)2-1-11-3-5-13(6-4-11)18(29)24-15(20(31)32)7-8-16(27)28;/h3-6,12,15H,1-2,7-10H2,(H,24,29)(H,27,28)(H,31,32)(H4,22,23,25,26,30);1H2/t12-,15+;/m1./s1
InChI key
AEFQSKJUVDZANQ-YLCXCWDSSA-N
assay
≥95% (HPLC)
form
powder
color
white to light yellow
solubility
DMSO: ≥5 mg/mL
storage temp.
2-8°C
Quality Level
相关类别
Application
使用洛美曲索水合物比较人GARFTase有效抑制剂的生物学活性。
Biochem/physiol Actions
甘氨酰胺核糖核苷酸甲酰基转移酶（GARFTase）是从头嘌呤合成所需的叶酸依赖性酶。 洛美曲索是GARFTase的有效抑制剂，但不会干扰叶酸合成中涉及的酶。 已在临床上测试了洛美曲索作为一种类似于甲氨蝶呤的抗叶酸药物，用于治疗各种癌症。 用洛美曲索治疗可迅速降低ATP和GTP水平，使细胞周期停滞并诱导细胞凋亡。 尽管核苷酸库的消耗会诱导p53表达，但洛美曲索在野生型和突变型表达p53的肿瘤细胞中均具有细胞毒性。 洛美曲索对CCRF-CEm白血病细胞具有细胞毒性，IC50为2.9 nM。
甘氨酰胺核糖核苷酸甲酰转移酶抑制剂
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
C Shih et al.
Advances in enzyme regulation, 38, 135-152 (1998-10-08)
Extensive biochemical and pharmacological evidence indicates that LY231514 is a novel antifolate antimetabolite. LY231514 is transported into cells mainly through the reduced folate carrier system and extensively metabolized to polyglutamated forms. The polyglutamates of LY231514 inhibit at least three key
A Tse et al.
The Journal of biological chemistry, 273(40), 25944-25952 (1998-09-25)
Mouse L1210 cell variants were selected for resistance to 5, 10-dideazatetrahydrofolate, a potent inhibitor of the first folate-dependent enzyme in de novo purine synthesis, glycinamide ribonucleotide formyltransferase. The drug-resistant phenotype selected was conditional to the folate compound used to support
G Jansen et al.
The Journal of biological chemistry, 273(46), 30189-30198 (1998-11-07)
CEM/MTX is a subline of human CCRF-CEM leukemia cells which displays >200-fold resistance to methotrexate (MTX) due to defective transport via the reduced folate carrier (RFC). CEM/MTX-low folate (LF) cells, derived by a gradual deprivation of folic acid from 2.3
X Lu et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 7(7), 2114-2123 (2001-07-13)
The impact of p53 status on cellular sensitivity to antifolate drugs has been examined in seven human cell lines (A549, MCF7, T-47D, CCRF-CEM, COR-L23, A2780, and HCT-116) and p53 nonfunctional counterparts of two of the cell lines (HCT-116/N7 and A2780/CP70).
Huiling Qi et al.
Cancer research, 66(11), 5875-5882 (2006-06-03)
The folate receptor (FR) type beta is a promising target for therapeutic intervention in acute myelogenous leukemia (AML), owing particularly to its selective up-regulation in the leukemic cells by all-trans retinoic acid (ATRA). Here we show, using KG-1 and MV4-11
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持